Despite the finding in SAVOR-TIMI 53 that HF hospitalization increased with Saxagliptin, this meta-analysis suggested that DPP4 inhibitors, as a class, are safe in patients with high CV risk, and actually demonstrated a trend towards reduced MI (Figure 2). Here, DPP4 is linked to hydrops fetalis.